Works matching DE "FULVESTRANT"

Results: 191
    1
    2

    Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort.

    Published in:
    Nature Communications, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41467-025-59210-6
    By:
    • Hu, Xichun;
    • Zhang, Qingyuan;
    • Sun, Tao;
    • Xiong, Huihua;
    • Li, Wei;
    • Teng, Yuee;
    • Lu, Yen-Shen;
    • Tseng, Ling-Ming;
    • Yan, Min;
    • Li, Hongsheng;
    • Pang, Danmei;
    • -Chen, Shin-Cheh;
    • Chen, Wenyan;
    • Jiang, Ou;
    • Wang, Jingfen;
    • Wu, Xinhong;
    • Wang, Xian;
    • Zang, Aimin;
    • Wang, Xiaojia;
    • Collins, Julie M.
    Publication type:
    Article
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20

    Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant.

    Published in:
    Breast Cancer Research, 2023, v. 25, n. 1, p. 1, doi. 10.1186/s13058-023-01701-9
    By:
    • Neven, P.;
    • Fasching, P. A.;
    • Chia, S.;
    • Jerusalem, G.;
    • De Laurentiis, M.;
    • Im, S.-A.;
    • Petrakova, K.;
    • Bianchi, G. V.;
    • Martín, M.;
    • Nusch, A.;
    • Sonke, G. S.;
    • De la Cruz-Merino, L.;
    • Beck, J. T.;
    • Zarate, J. P.;
    • Wang, Y.;
    • Chakravartty, A.;
    • Wang, C.;
    • Slamon, D. J.
    Publication type:
    Article
    21

    Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study.

    Published in:
    2022
    By:
    • Ozaki, Yukinori;
    • Aoyama, Yosuke;
    • Masuda, Jun;
    • Inagaki, Lina;
    • Kawai, Saori;
    • Shibayama, Tomoko;
    • Maeda, Tetsuyo;
    • Kurata, Mami;
    • Yoshida, Kazuyo;
    • Saeki, Sumito;
    • Hosonaga, Mari;
    • Fukada, Ippei;
    • Hara, Fumikata;
    • Kobayashi, Takayuki;
    • Kobayashi, Kokoro;
    • Miyake, Satoshi;
    • Takano, Toshimi;
    • Ueno, Takayuki;
    • Ohno, Shinji
    Publication type:
    journal article
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43

    Somatic BRCA2 Mutation-Positive Concurrent Accessory Male Breast Cancer (BC) and Non-Small Cell Lung Cancer (NSCLC): Excellent Efficacy of Palbociclib, Fulvestrant and Leuprolide in Platinum-Exposed and Endocrine-Refractory BC Associated with Cyclin D1 and FGFR1 Amplification and of Carboplatin, Paclitaxel and Radiation in NSCLC

    Published in:
    Case Reports in Oncology, 2019, v. 12, n. 2, p. 494, doi. 10.1159/000501304
    By:
    • Cheng, Yu;
    • Li, Ningjing;
    • Eapen, Ann;
    • Parajuli, Ritesh;
    • Mehta, Rita
    Publication type:
    Article
    44
    45

    Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

    Published in:
    British Journal of Cancer, 2015, v. 113, n. 4, p. 585, doi. 10.1038/bjc.2015.247
    By:
    • Quenel-Tueux, Nathalie;
    • Debled, Marc;
    • Rudewicz, Justine;
    • MacGrogan, Gaetan;
    • Pulido, Marina;
    • Mauriac, Louis;
    • Dalenc, Florence;
    • Bachelot, Thomas;
    • Lortal, Barbara;
    • Breton-Callu, Christelle;
    • Madranges, Nicolas;
    • de Lara, Christine Tunon;
    • Fournier, Marion;
    • Bonnefoi, Hervé;
    • Soueidan, Hayssam;
    • Nikolski, Macha;
    • Gros, Audrey;
    • Daly, Catherine;
    • Wood, Henry;
    • Rabbitts, Pamela
    Publication type:
    Article
    46
    47
    48
    49

    Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

    Published in:
    NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00571-w
    By:
    • Hopcroft, Lorna;
    • Wigmore, Eleanor M.;
    • Williamson, Stuart C.;
    • Ros, Susana;
    • Eberlein, Cath;
    • Moss, Jennifer I.;
    • Urosevic, Jelena;
    • Carnevalli, Larissa S.;
    • Talbot, Sara;
    • Bradshaw, Lauren;
    • Blaker, Catherine;
    • Gunda, Sreeharsha;
    • Owenson, Venetia;
    • Hoffman, Scott;
    • Sutton, Daniel;
    • Jones, Stewart;
    • Goodwin, Richard J. A.;
    • Willis, Brandon S.;
    • Rooney, Claire;
    • DeBruin, Elza
    Publication type:
    Article
    50

    Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer.

    Published in:
    NPJ Breast Cancer, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41523-023-00544-z
    By:
    • Elias, Anthony D.;
    • Spoelstra, Nicole S.;
    • Staley, Alyse W.;
    • Sams, Sharon;
    • Crump, Lyndsey S.;
    • Vidal, Gregory A.;
    • Borges, Virginia F.;
    • Kabos, Peter;
    • Diamond, Jennifer R.;
    • Shagisultanova, Elena;
    • Afghahi, Anosheh;
    • Mayordomo, Jose;
    • McSpadden, Tessa;
    • Crawford, Gloria;
    • D'Alessandro, Angelo;
    • Zolman, Kathryn L.;
    • van Bokhoven, Adrie;
    • Zhuang, Yonghua;
    • Gallagher, Rosa I.;
    • Wulfkuhle, Julia D.
    Publication type:
    Article